证券代码：301293 证券简称：三博脑科 公告编号：2025-050 二、备查文件 私募投资基金备案证明。 三博脑科医院管理集团股份有限公司董事会 2025 年 12 月 19 日 关于参与设立的投资基金完成私募基金备案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为不断完善三博脑科医院管理集团股份有限公司（以下简称"公司"）产业链， 不断提升公司的临床诊疗水平，进一步增强公司的科技赋能，同时为充分利用资 本市场平台优势，借助专业投资机构的管理水平和投资经验，公司作为有限合伙 人与基金管理人深圳前海元明资产管理有限公司、普通合伙人天津元明管理咨询 合伙企业（有限合伙）及其他有限合伙人共同投资设立天津元明海河脑科学创业 投资合伙企业（有限合伙）（以下简称"基金"），具体内容详见公司于 2025 年 9 月 9 日在巨潮资讯网披露的《关于与专业投资机构共同投资设立基金的公告》（公 告编号：2025-037）。 近日，深圳前海元明资产管理有限公司已根据《证券投资基金法》和《私募 投资基金监督管理暂行办法》等法律法规的要求，在中国证券投资基金业协会完 成对 ...

据智通财经12月19日讯，据国家药监局消息，12月18日，国家药监局在北京召开脑机接口医疗器械工作 推进会。会议听取高等院校、科研院所、医疗机构相关专家学者和研发企业代表意见建议。国家药监局 党组成员、副局长雷平出席会议并讲话。 会议要求，要深入贯彻落实党的二十届四中全会精神，深刻领会脑机接口作为前瞻布局未来产业的重要 战略意义；要坚持安全有效为首要前提，创新审评监管方法，构建标准体系，加强技术指导服务；要加 强跨部门合作，联手产学研医各方，合力解决关键技术问题，完善产业链供应链；要落实企业主体责 任，以问题为导向，提升产品可靠性和整体竞争力，积极推动脑机接口器械更快更好服务临床、惠及患 者。 国家药监局器械注册司、标管中心、器审中心负责同志及有关人员参加会议。 相关市场板块分析 医疗器械与康复设备：脑机接口技术率先在医疗康复领域落地，多家公司产品进入临床试验阶段，相关 医疗器械企业迎来技术升级与需求扩张，市场潜力巨大。 人工智能与大数据：脑机接口依赖高精度算法与海量数据处理，AI企业在脑电信号解码、情绪识别、 脑电大模型等领域深度布局，推动技术迭代。 消费电子与智能穿戴：非侵入式脑机接口在游戏、教育、疲劳监 ...

Core Insights - The brain-computer interface (BCI) sector in China has made significant advancements, enabling paralyzed patients to control wheelchairs and robotic dogs through thought [1] - The market for brain-computer interfaces is projected to grow substantially, with estimates of 3.2 billion yuan in 2024 and reaching 6.14 billion yuan by 2028 in China [2] - The global BCI market is expected to grow from approximately 2.62 billion USD in 2024 to 12.4 billion USD by 2034, with a compound annual growth rate (CAGR) of 17.35% over the next decade [2] Industry Developments - The Chinese Academy of Sciences has achieved breakthroughs in invasive BCI technology, improving signal extraction efficiency by 15% to 20% in noisy environments [1] - The end-to-end latency for the new BCI system has been reduced to under 100 milliseconds, enhancing user experience compared to the natural physiological delay of 200 milliseconds [1] - The BCI industry is expected to benefit from policy support, technological innovation, and increased capital investment, leading to significant growth opportunities in healthcare and consumer markets [2] Company Highlights - Innovation Medical (002173) is involved in the only invasive BCI system in China that has reached Phase III clinical trials, comparable to Neuralink [3] - iFlytek (002230) leverages AI technology to develop BCI applications in collaboration with universities, expanding into the healthcare sector [3] - Lenovo (00992) has launched the world's first consumer-grade BCI headset, achieving a thought input speed of 12-15 words per minute with over 85% accuracy [3] - Sanbo Brain Science (301293) has conducted the first invasive BCI trial in China, providing new treatment options for stroke and paraplegic patients [3] - Gaode Infrared (002414) is developing a 65,000-channel implantable chip, significantly increasing channel density compared to Neuralink [3] - Tom Cat (300459) is exploring the intersection of AI and brain science in children's education and rehabilitation [4] - Hanwei Technology (300007) has a subsidiary involved in flexible electrodes and brain signal acquisition technology, showing potential for technology transfer [4]

Group 1: Industry Overview - The brain-computer interface (BCI) market in China is projected to reach 3.2 billion yuan in 2024 and is expected to grow to 6.14 billion yuan by 2028 [2] - The global BCI market is estimated to be approximately 2.62 billion USD in 2024, with a forecasted increase to 2.94 billion USD in 2025, and a potential growth to 12.4 billion USD by 2034, reflecting a compound annual growth rate (CAGR) of 17.35% over ten years [2] - The BCI industry is anticipated to benefit from dual drivers of policy and technology, presenting significant opportunities for growth [2] Group 2: Technological Advancements - Recent breakthroughs in invasive BCI technology have enabled a high-level paraplegic patient to control a smart wheelchair and robotic dog using brain signals, achieving a 15% to 20% improvement in brain control performance [1] - The new system developed by the research team has reduced end-to-end latency to under 100 milliseconds, which is lower than the physiological delay of 200 milliseconds in natural neural pathways, enhancing user experience [1] Group 3: Company Developments - Innovation Medical holds a 40% stake in Bole Medical and leads the only invasive BCI system (BCI-4000) in China that has entered Phase III clinical trials, comparable to Neuralink [3] - iFlytek leverages its AI technology to collaborate with universities on BCI applications, expanding into the healthcare sector [3] - Lenovo has launched the world's first consumer-grade BCI headset, "Lenovo Mind X1," which can achieve a typing speed of 12-15 characters per minute with over 85% accuracy, marking a significant step towards practical BCI applications [3] - Sanbo Neuroscience has completed China's first invasive BCI trial, providing new treatment options for stroke and paraplegic patients through wireless brain signal acquisition [3] - Gaode Infrared's subsidiary has developed a 65,000-channel implantable chip, which has a channel density 20 times that of Neuralink, enabling bidirectional information read/write capabilities [3] Group 4: Emerging Applications - Tom Cat is exploring the integration of BCI technology in children's education and rehabilitation, aiming to create a new model of "AI + brain science" [4] - Hanwei Technology's subsidiary is involved in flexible electrodes and brain signal acquisition technology, showing potential for technology commercialization [4]

Core Viewpoint - The brain-computer interface (BCI) industry is experiencing significant advancements, particularly with the successful completion of a second invasive clinical trial, which marks a transition from 2D control to 3D interaction in real-world applications [2][6][10]. Group 1: Clinical Trial Progress - The second invasive BCI clinical trial was successfully completed, allowing a high-level paraplegic patient to control a smart wheelchair and robotic dog using brain signals [6][8]. - The research team developed a high-throughput wireless invasive BCI system (WRS01), enabling stable control of devices in real-life scenarios after several weeks of training [6][7]. - Key technological breakthroughs include advanced neural data compression techniques that enhance brain control performance by 15%-20% even in noisy environments [6][7]. Group 2: Industry Development and Policy Support - The BCI industry is entering a rapid development phase due to policy incentives and technological innovations, with expectations for continued government support [4][11]. - The industry is characterized by a collaborative ecosystem involving policy, research, industry, and capital, which is essential for scaling and upgrading the BCI sector [10][11]. - Local governments are implementing two-step strategies to promote BCI product and clinical development by 2027 and 2030, respectively, providing a framework for local enterprises [11][12]. Group 3: Investment Opportunities - Investment opportunities are expected to increase as the BCI industry transitions from research to commercialization, with a focus on companies with strong self-research capabilities or partnerships with leading academic institutions [11][12]. - Three main investment lines are suggested: domestic mapping of invasive BCI advanced industry chains, non-invasive BCI products in consumer scenarios, and downstream application-related companies [12].

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant advancements, particularly with the successful completion of a second invasive clinical trial in China, which marks a transition from 2D control to 3D interaction in real-world applications [1][4]. Group 1: Clinical Trial Progress - The second invasive BCI clinical trial was conducted by the Chinese Academy of Sciences in collaboration with Fudan University and other entities, enabling a high-level paraplegic patient to control a smart wheelchair and robotic dog using brain signals [4]. - The system developed allows for stable control of devices in real-life scenarios, with a reported 15%-20% improvement in brain control performance due to advanced data compression techniques [4][5]. Group 2: Market Reaction - Following the announcement of the clinical trial progress, BCI-related stocks surged, with companies like Innovation Medical rising over 8% and others like BeiYikang and Sanbo Neuroscience also showing significant gains [1]. Group 3: Industry Outlook - Analysts predict that the BCI industry is entering a rapid growth phase due to supportive policies and technological innovations, with expectations for continued government backing and increased investment opportunities [2][8]. - The industry is characterized by a collaborative ecosystem involving policy, research, industry, and capital, which is essential for its sustainable development [7]. Group 4: Investment Recommendations - Investment firms suggest focusing on three main areas: domestic mapping of advanced invasive BCI technologies, non-invasive BCI products in consumer markets, and downstream applications of BCI technology [9].

证券代码：301293 证券简称：三博脑科 公告编号：2025-049 三博脑科医院管理集团股份有限公司 关于与专业投资机构共同投资认购的基金存续期变更并签订补充协 议的公告 算，其中投资期为 4 年，退出期为 3 年。 一、与专业投资机构共同投资概述 为不断完善三博脑科医院管理集团股份有限公司（以下简称"公司"）产业链， 不断提升公司的临床诊疗水平，进一步增强公司的科技赋能，同时为充分利用资 本市场平台优势，借助专业投资机构的管理水平和投资经验，公司以有限合伙人 身份认购北脑一期（北京）股权投资中心（有限合伙）（以下简称"基金"、"合 伙企业"）部分份额，合伙企业募集资金总额为 9,000 万元，公司以自有资金 1,000 万元认购 11.11%的基金份额。具体内容详见公司于 2025 年 8 月 27 日在巨潮资 讯网（www.cninfo.com.cn）披露的《关于与专业投资机构共同投资认购基金份额 的公告》。 二、存续期变更情况说明 鉴于基金的原定存续期为 7 年，到期日为 2032 年 11 月 19 日，与基金的有 限合伙人之一北京北脑创业投资基金（有限合伙）的到期日（2031 年 2 月 17 ...

Group 1 - The core viewpoint of the article highlights the financial performance and market position of Sanbo Brain Science, indicating a significant increase in revenue but a decline in net profit [1] - As of December 12, Sanbo Brain Science's stock closed at 54.12 yuan, with a rolling PE ratio of 132.55 times and a total market capitalization of 11.148 billion yuan [1] - The company ranks 38th in the medical services industry, which has an average PE ratio of 49.50 times and a median of 61.79 times [1] Group 2 - For the third quarter of 2025, Sanbo Brain Science reported a revenue of 1.273 billion yuan, representing a year-on-year increase of 20.26% [1] - The net profit for the same period was 83.6282 million yuan, showing a year-on-year decrease of 20.01%, with a sales gross margin of 24.87% [1] - A total of 8 institutions held shares in Sanbo Brain Science, with a combined holding of 41.1976 million shares valued at 2.408 billion yuan [1]

证券日报网讯12月11日晚间，三博脑科（301293）发布公告称，持股5%以上股东 TBP3Doctors(HK)Limited于2025年9月11日至12月10日通过集中竞价减持100万股，占剔除回购账户后总 股本0.493%，减持计划届满。 ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-047 三博脑科医院管理集团股份有限公司 关于对子公司担保进展公告 一、担保情况概述 三博脑科医院管理集团股份有限公司（以下简称"公司"）分别于 2025 年 10 月 27 日、2025 年 11 月 12 日召开了第三届董事会第十五次会议和 2025 年第二 次临时股东会，审议通过了《关于为子公司提供担保额度预计的议案》，同意公 司为下属公司的融资提供担保额度总计不超过人民币 92,442.83 万元，其中有两 笔是为控股子公司西安三博脑科医院有限公司（以下简称"西安三博"）提供的担 保，两笔担保额度分别为 5,000 万元和 4,135.95 万元。担保方式包括但不限于保 证、抵押；担保期限以实际签署的担保协议为准。公司可以根据实际情况，在上 述额度范围内，在符合要求的担保对象之间进行担保额度的调剂，对资产负债率 超过 70%的担保对象提供担保，仅能从资产负债率超过 70%（审议担保额度时） 的担保对象处获得担保额度。 具体内容详见公司于 2025 年 10 月 28 日在巨潮资讯网披露的《关于为子公 司提供担保额度预计的公告》。 二、担保 ...